[Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].

S. Menif (1) , N. Ben Romdhane (2) , R. Hafsia (3)

1 LR11IPT07 - Laboratoire d'hématologie moléculaire et cellulaire
2 Laboratoire d'hématologie
3 Service d'hématologie

Hypereosinophilic syndromes (HES) are a heterogeneous group of disorders characterized by marked peripheral blood and tissue eosinophilia resulting in organ damage. Recent advances in molecular biology have led to the identification of a FIP1L1-PDGFRA fusion gene as a recurrent abnormality in some patients with HES. This fusion gene results from a cryptic 4q12 interstitial deletion involving an 800 kb region. Recent reports indicate that this subtype of HES is imatinib responsive with rapid and complete haematological remissions. Here we report two patients successfully treated with imatinib.

Mots clés: Hypereosinophilic syndrome; FIP1L1-PDGFRA; Imatinib

Domaines: Sciences du Vivant [q-bio]

S. Menif, N. Ben Romdhane, R. Hafsia. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].. La Revue de Médecine Interne, 2008, 29 (1), pp.65-7. ⟨10.1016/j.revmed.2007.09.036⟩. ⟨pasteur-00871496⟩